Altimmune, Inc. focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatitis.
Market Cap | 745.251 Million | Shares Outstanding | 49.159 Million | Avg 30-day Volume | 1.402 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | |
Price to Revenue | 189.6118 | Debt to Equity | 0.022 | EBITDA | -88.307 Million |
Price to Book Value | 3.0698 | Operating Margin | -2670.1276 | Enterprise Value | 432.034 Million |
Current Ratio | 13.404 | EPS Growth | 0 | Quick Ratio | 12.861 |
1 Yr BETA | 1.1664 | 52-week High/Low | 23.49 / 3.83 | Profit Margin | -2619.2678 |
Operating Cash Flow Growth | 3.3163 | Altman Z-Score | 16.1957 | Free Cash Flow to Firm | -58.805 Million |
Earnings Report | 2023-03-15 |
Please sign in first
none
20 Thousand total shares from 1 transactions
61.4 Thousand total shares from 5 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
EISENSTADT RICHARD I CHIEF FINANCIAL OFFICER |
|
12,010 | 2023-01-31 | 4 |
GARG VIPIN K PRESIDENT AND CEO |
|
238,601 | 2023-01-31 | 13 |
ROBERTS M SCOT CHIEF SCIENTIFIC OFFICER |
|
24,944 | 2023-01-31 | 6 |
HARRIS MATTHEW SCOTT CHIEF MEDICAL OFFICER |
|
17,900 | 2023-01-31 | 4 |
JORDT RAYMOND M CHIEF BUSINESS OFFICER |
|
0 | 2023-01-03 | 2 |
|
8,498 | 2022-12-22 | 2 | |
|
20,484 | 2022-11-18 | 4 | |
|
23,500 | 2022-09-29 | 1 | |
|
23,500 | 2022-09-29 | 1 | |
|
23,500 | 2022-09-29 | 2 | |
|
23,500 | 2022-09-29 | 1 | |
|
23,500 | 2022-09-29 | 2 | |
BROWN WILLIAM MICHAEL CHIEF FINANCIAL OFFICER |
|
17,721 | 2021-07-31 | 0 |
VENROCK HEALTHCARE CAPITAL PARTNERS III, L.P. VHCP CO-INVESTMENT HOLDINGS III, LLC VENROCK HEALTHCARE CAPITAL PARTNERS II, L.P. |
|
No longer subject to file | 2021-02-25 | 0 |
|
No longer subject to file | 2020-05-14 | 0 | |
VELOCITY PHARMACEUTICAL HOLDINGS LLC VELOCITY PHARMA MANAGEMENT, LLC |
|
1,887,250 | 2019-07-12 | 0 |
TASKER SYBIL CHIEF MEDICAL OFFICER |
|
0 | 2019-06-17 | 0 |
|
No longer subject to file | 2018-10-02 | 0 | |
ENRIGHT WILLIAM PRESIDENT AND CEO |
|
365,839 | 2018-05-25 | 0 |
|
2,161,802 | 2018-02-13 | 0 | |
|
1,152,600 | 2017-12-28 | 0 | |
|
0 | 2017-10-13 | 1 | |
CZEREPAK ELIZABETH CFO AND EVP CORP. DEVELOPMENT |
|
0 | 2017-09-22 | 0 |
REDMONT VAXN CAPITAL HOLDINGS, LLC |
|
0 | 2017-05-04 | 0 |
|
197,700 | 2017-01-20 | 0 | |
|
205,004 | 2017-01-04 | 0 | |
MACNEILL PHILIP VP, CFO, TREASURER, SECRETARY |
|
126,346 | 2016-12-21 | 0 |
|
No longer subject to file | 2016-12-07 | 0 | |
|
908,055 | 2016-11-22 | 0 | |
|
27,544 | 2015-03-11 | 0 | |
CHANG LINDA L SVP, CFO & SECRETARY |
|
30,000 | 2015-01-07 | 0 |
|
0 | 2014-12-31 | 0 | |
|
0 | 2014-12-31 | 0 | |
COOK FRANCESCA M SVP, POLICY & GOV'T AFFAIRS |
|
0 | 2014-12-08 | 0 |
MORGES WAYNE SVP, REG. AFFAIRS & QUALITY |
|
0 | 2014-12-08 | 0 |
KARP JORDAN P SVP, GENERAL COUNSEL |
|
0 | 2012-12-03 | 0 |
FUERST THOMAS RICHARD EVP, CHIEF SCIENTIFIC OFFICER |
|
0 | 2011-12-01 | 0 |
|
0 | 2011-06-23 | 0 | |
RIDDLE VALERIE D SVP, MEDICAL DIRECTOR |
|
44,436 | 2011-05-25 | 0 |
REINHART CHARLES A. III SVP, CHIEF FINANCIAL OFFICER |
|
0 | 2010-12-08 | 0 |
|
4,253,057 | 2010-11-03 | 0 | |
|
6,347,614 | 2010-11-03 | 0 | |
MPM BIOVENTURES III PARALLEL FUND, L.P. MPM BIOVENTURES III GMBH & CO. BETEILIGUNGS KG MPM ASSET MANAGEMENT INVESTORS 2004 BVIII LLC |
|
6,347,614 | 2010-11-03 | 0 |
|
0 | 2010-06-23 | 0 | |
FUSCO JOAN SVP, OPERATIONS |
|
0 | 2010-05-06 | 0 |
CAMUT CHRISTOPHER C VP, GOV'T CONTRACTS |
|
No longer subject to file | 2010-01-21 | 0 |
WRIGHT DAVID P PRESIDENT AND CEO |
|
399,500 | 2009-12-11 | 0 |
PRICE KEVIN PRESIDENT - PHARMATHENE UK,LTD |
|
0 | 2009-01-21 | 0 |
|
5,109,690 | 2007-08-03 | 0 | |
|
1,200,000 | 2007-08-03 | 0 | |
|
996 | 2007-08-03 | 0 | |
|
22,500 | 2007-08-03 | 0 | |
SCHELLHAMMER WAYNE A |
|
22,500 | 2007-08-03 | 0 |
|
611,980 | 2007-08-03 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-02-02 17:11:14 -0500 | 2023-02-01 | M | 6,166 | d | 12,332 | direct | ||||||||||
2023-02-02 17:11:14 -0500 | 2023-02-01 | F | 2,183 | $13.78 | d | 14,456 | direct | |||||||||
2023-02-02 17:11:14 -0500 | 2023-02-01 | M | 6,166 | a | 16,639 | direct | ||||||||||
2023-02-02 17:10:41 -0500 | 2023-02-01 | M | 6,166 | d | 12,332 | direct | ||||||||||
2023-02-02 17:10:41 -0500 | 2023-02-01 | F | 2,183 | $13.78 | d | 17,900 | direct | |||||||||
2023-02-02 17:10:41 -0500 | 2023-02-01 | M | 6,166 | a | 20,083 | direct | ||||||||||
2023-02-02 17:09:43 -0500 | 2023-02-01 | M | 16,546 | d | 33,090 | direct | ||||||||||
2023-02-02 17:09:43 -0500 | 2023-02-01 | F | 7,658 | $13.78 | d | 238,601 | direct | |||||||||
2023-02-02 17:09:43 -0500 | 2023-02-01 | M | 16,546 | a | 246,259 | direct | ||||||||||
2023-02-02 17:11:14 -0500 | 2023-01-31 | A | 1,436 | $10.21 | a | 10,473 | direct | |||||||||
2023-02-02 17:10:41 -0500 | 2023-01-31 | A | 1,296 | $10.21 | a | 13,917 | direct | |||||||||
2023-02-02 17:09:43 -0500 | 2023-01-31 | A | 1,938 | $10.21 | a | 229,713 | direct | |||||||||
2023-02-02 17:09:00 -0500 | 2023-01-31 | A | 1,172 | $10.21 | a | 12,010 | direct | |||||||||
2023-02-01 17:33:13 -0500 | 2023-01-30 | A | 302,900 | a | 302,900 | direct | ||||||||||
2023-02-01 17:33:13 -0500 | 2023-01-30 | A | 107,100 | a | 107,100 | direct | ||||||||||
2023-02-01 17:31:51 -0500 | 2023-01-30 | A | 37,100 | a | 37,100 | direct | ||||||||||
2023-02-01 17:31:51 -0500 | 2023-01-30 | A | 105,000 | a | 105,000 | direct | ||||||||||
2023-02-01 17:31:05 -0500 | 2023-01-30 | A | 37,100 | a | 37,100 | direct | ||||||||||
2023-02-01 17:31:05 -0500 | 2023-01-30 | A | 105,000 | a | 105,000 | direct | ||||||||||
2023-02-01 17:30:31 -0500 | 2023-01-30 | A | 37,100 | a | 37,100 | direct | ||||||||||
2023-02-01 17:30:31 -0500 | 2023-01-30 | A | 105,000 | a | 105,000 | direct | ||||||||||
2023-01-04 16:06:00 -0500 | 2023-01-03 | A | 37,500 | a | 37,500 | direct | ||||||||||
2023-01-04 16:06:00 -0500 | 2023-01-03 | A | 125,000 | a | 125,000 | direct | ||||||||||
2023-01-03 17:59:54 -0500 | 2022-12-31 | M | 12,500 | d | 37,500 | direct | ||||||||||
2023-01-03 17:59:54 -0500 | 2022-12-31 | F | 3,028 | $16.45 | d | 10,838 | direct | -3.1735 | 5.1317 | 5.1317 | 6 | -5.6718 | 4 | |||
2023-01-03 17:59:54 -0500 | 2022-12-31 | M | 12,500 | a | 13,866 | direct | -3.1735 | 5.1317 | 5.1317 | 6 | -5.6718 | 4 | ||||
2022-12-22 16:05:36 -0500 | 2022-12-22 | M | 20,000 | $2.60 | a | 28,498 | direct | -3.3268 | 1.9569 | 7.3059 | 5 | -3.8487 | 3 | |||
2022-12-22 16:05:36 -0500 | 2022-12-22 | M | 20,000 | d | 0 | direct | ||||||||||
2022-12-22 16:05:36 -0500 | 2022-12-22 | S | 20,000 | $15.01 | d | 8,498 | direct | yes | -3.3268 | 1.9569 | 7.3059 | 5 | -3.8487 | 3 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
ALTIMMUNE INC ALT | 2023-02-03 22:15:03 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 21:45:03 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 21:15:03 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 20:45:06 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 20:15:04 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 19:45:03 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 19:15:04 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 18:45:03 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 18:15:03 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 17:45:03 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 17:15:04 UTC | 4.0397 | 0.5303 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 16:45:04 UTC | 4.042 | 0.528 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 16:15:03 UTC | 4.042 | 0.528 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 15:45:03 UTC | 4.042 | 0.528 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 15:15:03 UTC | 4.042 | 0.528 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 14:45:04 UTC | 3.8375 | 0.4825 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 14:15:04 UTC | 3.8375 | 0.4825 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 13:45:03 UTC | 3.8375 | 0.4825 | 2000000 |
ALTIMMUNE INC ALT | 2023-02-03 13:15:03 UTC | 3.8375 | 0.4825 | 1900000 |
ALTIMMUNE INC ALT | 2023-02-03 12:45:03 UTC | 3.8375 | 0.4825 | 1900000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|